Biotech Train Heads for Gains

The biotechnology business has ridden a roller coaster in the financial markets for the past 18 months. The gyrations have been enough to make even the most stalwart investor swallow hard. Enthusiastic over the potential of human genome sequencing and depressed about the downturn in the dot-com markets, investors drove up values in biotech stocks by 300 percent and more. But by spring, the high-tech stocks' Titanic pitches had finally helped tow biotech stocks down by 50 percent. Now, with analy

| 9 min read

Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share

The ride could have been even more dizzying. Compared to last year's sinking Internet stocks, the life science issues have fared well, even benefiting from high-tech woes by attracting public funding and private venture capital. Analysts still express concern, however. If wary investors don't turn back to biotech as fast as the experts think they should, or if the big pharmaceutical companies fail to achieve challenging goals in bringing to market new blockbuster drugs (that can generate $1 billion in sales), the slowdown may hinder smaller companies from raising capital to fund research and development, launch new products, or simply stay in business.

Even if stock values rise, analysts still expect some jobs to be lost and others to be created as consolidations sweep the pharmaceutical and biotech sectors this year. While some biotech companies will go out of business, competitors eager to purchase talent and technologies at bargain prices ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Ted Agres

    This person does not yet have a bio.

Published In

Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide